Tolerance and safety of different concentrations of chlorhexidine for peripartum vaginal and infant washes: HIVNET 025.

Wilson CM, Gray G, Read JS, Mwatha A, Lala S, Johnson S, Violari A, Sibiya PM, Fleming TR, Koonce A, Vermund SH, McIntyre J
J Acquir Immune Defic Syndr. 2004 35 (2): 138-43

PMID: 14722445 · PMCID: PMC2753236 · DOI:10.1097/00126334-200402010-00006

BACKGROUND - There is a continuing need to evaluate sustainable interventions for prevention of mother-to-child transmission (MTCT) of HIV type 1. We evaluated different concentrations (0.25%, 1%, and 2%) of chlorhexidine (CHX) for perinatal maternal and infant washes to identify the maximum tolerable concentration of CHX for such an intervention.

METHODS - Women were enrolled during their third trimester at the maternity unit of the Chris Hani Baragwanath Hospital in Soweto, South Africa, and perinatal maternal and infant washes were completed. Subjective maternal symptoms as well as infant examinations were used to assess tolerability of the washes.

RESULTS - The 0.25% concentration of CHX was well tolerated by the mothers (n = 29). Ten of 79 women (13%) with 1% CHX washes complained of mild vaginal area burning or itching, and washes were stopped in 5 (6%). Twenty-three of 75 women (31%) in the 2% CHX wash group had subjective complaints, and the washes were stopped in 12 (16%). There were no clinical indications of toxicity of the CHX washes among infants.

CONCLUSION - A 1% solution of CHX appears to be a safe and tolerable concentration of CHX for consideration in an MTCT prevention trial.

MeSH Terms (16)

Acquired Immunodeficiency Syndrome Baths Chlorhexidine Disinfectants Female Follow-Up Studies Humans Hygiene Infant, Newborn Infectious Disease Transmission, Vertical Postpartum Period Pregnancy Pregnancy Complications, Infectious Pregnancy Trimester, Third Time Factors Vagina

Connections (1)

This publication is referenced by other Labnodes entities: